Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH), classified as a growth hormone secretagogue. It stimulates the pituitary gland to release the body's own growth hormone rather than supplying growth hormone directly.

What does research suggest tesamorelin does?

Controlled clinical trials support tesamorelin's approved use in reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Its mechanism works through the GHRH pathway and the growth hormone/IGF-1 axis. Uses beyond the approved indication are not established or validated.

Is tesamorelin FDA-approved?

Tesamorelin is approved as a prescription medicine (brand name Egrifta) for HIV-associated lipodystrophy in some jurisdictions. It is prescription-only, and its use outside that approved indication is unapproved.

What are the reported side effects of tesamorelin?

Reported effects include injection-site reactions, joint pain, and fluid retention, which are consistent with stimulation of the growth hormone axis. Complete safety information appears in the approved prescribing documentation.

Is tesamorelin legal?

Tesamorelin is a prescription-only medicine where it is approved. Legal status varies by country, and its sale or use as an unregulated research chemical falls outside approved medical channels. peptides.cx is an educational reference and not the seller; where a shop link appears it is labelled advertising, not a recommendation to use it. Lawful access requires a prescription and clinical supervision.

How is tesamorelin different from peptides like sermorelin or CJC-1295?

All three act on the GHRH pathway to prompt the pituitary to release growth hormone, but tesamorelin is a specifically stabilized GHRH analogue that reached formal regulatory approval for one defined medical condition. Sermorelin is a shorter GHRH fragment with a different history, and CJC-1295 is a research compound without that approval. Being related in mechanism does not make them interchangeable, and only tesamorelin has an approved prescription indication.

If tesamorelin is an approved medicine, why does it appear in research-chemical listings?

Approval applies to a specific branded product, dose form, and medical indication delivered under prescription and supervision. Material sold as a research chemical sits entirely outside that framework: it is not the approved product, is not quality-assured for human use, and carries no medical oversight. The existence of an approved version does not make unregulated supply equivalent or safe.

Is a GHRH analogue the same as taking growth hormone directly?

No. Tesamorelin works upstream, stimulating the body's own pituitary to release growth hormone through the GHRH pathway, rather than supplying growth hormone itself. This is a genuine mechanistic distinction often blurred in casual discussion, but both approaches affect the same hormonal axis and carry real physiological consequences, which is why medical supervision matters.

Where can I buy Tesamorelin and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Growth Hormone Secretagogue

Buy Tesamorelin – Vendors, Prices, Testing and Evidence

Buy Tesamorelin

Also known as: Egrifta · TH9507

Evidence grade B — Human, limitedRisk flag

Short answer

A GHRH analogue approved as a prescription medicine for a specific condition. Research-market use is unapproved and unsupervised.

Where can you buy Tesamorelin?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone.

What is not established?

Clinical evidence supports its approved indication; other uses are not established.

Safety

A prescription medicine with real hormonal effects; must be used under medical supervision. Not for unsupervised use.

Regulatory status

Approved as a prescription medicine (Egrifta) for HIV-associated lipodystrophy in some jurisdictions; prescription-only.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy Tesamorelin: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	Tesamorelin research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

Tesamorelin research product

Code PEPTIDES10 −10% · discount code details

What is it?

Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone.

Research and evidence

Tesamorelin, also known by the brand name Egrifta and the research code TH9507, is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH). It belongs to the class of growth hormone secretagogues, compounds that act on the body's own regulatory pathways rather than delivering growth hormone directly. Tesamorelin works by binding to GHRH receptors in the pituitary gland and stimulating the endogenous release of growth hormone, which in turn influences the growth hormone and IGF-1 axis. Its structural modifications make it more resistant to enzymatic breakdown than native GHRH, giving it a more usable pharmacological profile.

The primary reason tesamorelin is studied and clinically used is its regulatory-approved indication: it is approved as a prescription medicine in some jurisdictions for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Within that indication, controlled clinical trials support its effects, which is why the compound carries a relatively solid evidence rating compared with many research peptides. It is important to be clear about the boundaries of that evidence: the human clinical data that supports tesamorelin is tied to its approved use, and the many other applications discussed in fitness, anti-aging, and body-composition contexts are not established, not approved, and have not been validated by comparable trials. Preclinical work has characterised its effects on the growth hormone axis, but animal and in-vitro findings do not translate directly into proven human benefits outside the approved setting.

Because tesamorelin produces real hormonal effects, the honest evidence picture also involves genuine safety considerations. As a prescription medicine, it is intended to be used only under medical supervision; unsupervised research-market use falls outside any approved framework and carries risk. Reported effects include injection-site reactions, joint pain, and fluid retention, consistent with growth-hormone-axis stimulation. peptides.cx presents this information as an educational reference only. It is not medical advice and does not recommend use, and peptides.cx is not the seller; where a shop link appears it is labelled advertising, not a recommendation to use tesamorelin, and no dosing or protocol guidance is given. A prescription-only medicine lawfully requires a prescription and clinical supervision, and obtaining it without them is unlawful in many countries and can be dangerous. Anyone considering anything that affects hormonal systems should consult a qualified healthcare professional.

Evidence grade: B

Clinical evidence supports its approved indication; other uses are not established. GH-axis effects characterised preclinically.

Human evidence

Clinical evidence supports its approved indication; other uses are not established.

Animal and preclinical evidence

GH-axis effects characterised preclinically.

Proposed mechanisms

Stimulates endogenous growth-hormone release via the GHRH pathway

Safety concerns and known side effects

A prescription medicine with real hormonal effects; must be used under medical supervision. Not for unsupervised use.

Injection-site reactions
Joint pain
Fluid retention reported

Regulatory status

Approved as a prescription medicine (Egrifta) for HIV-associated lipodystrophy in some jurisdictions; prescription-only.

Tesamorelin research timeline

1980s
Growth-hormone-releasing hormone (GHRH) is characterized, establishing the pituitary pathway that tesamorelin was later designed to engage.
1990s–2000s
A stabilized GHRH analogue (code-named TH9507) is developed by a biopharmaceutical company to resist enzymatic breakdown and extend activity relative to native GHRH.
2000s
Human trials evaluate the compound for reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy, its eventual approved indication.
2010
The compound is approved by the U.S. FDA under the brand name Egrifta for that specific HIV-related indication, making it a prescription-only medicine.
2010s
Post-approval and investigator studies explore other GH-axis effects (including exploratory work on cognition and liver fat), which remain outside its approved use.
early 2020s
Despite an approved medical use, the peptide circulates in unregulated research-chemical channels where quality and unsupervised use raise safety concerns.

Frequently asked questions about Tesamorelin

What is tesamorelin?: Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH), classified as a growth hormone secretagogue. It stimulates the pituitary gland to release the body's own growth hormone rather than supplying growth hormone directly.
What does research suggest tesamorelin does?: Controlled clinical trials support tesamorelin's approved use in reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Its mechanism works through the GHRH pathway and the growth hormone/IGF-1 axis. Uses beyond the approved indication are not established or validated.
Is tesamorelin FDA-approved?: Tesamorelin is approved as a prescription medicine (brand name Egrifta) for HIV-associated lipodystrophy in some jurisdictions. It is prescription-only, and its use outside that approved indication is unapproved.
Is tesamorelin safe?: Tesamorelin has real hormonal effects and is intended for use only under medical supervision. Unsupervised research-market use falls outside any approved framework and carries risk. Its safety profile is best understood within the controlled clinical setting for which it was approved.
What are the reported side effects of tesamorelin?: Reported effects include injection-site reactions, joint pain, and fluid retention, which are consistent with stimulation of the growth hormone axis. Complete safety information appears in the approved prescribing documentation.
Is tesamorelin legal?: Tesamorelin is a prescription-only medicine where it is approved. Legal status varies by country, and its sale or use as an unregulated research chemical falls outside approved medical channels. peptides.cx is an educational reference and not the seller; where a shop link appears it is labelled advertising, not a recommendation to use it. Lawful access requires a prescription and clinical supervision.
How is tesamorelin different from peptides like sermorelin or CJC-1295?: All three act on the GHRH pathway to prompt the pituitary to release growth hormone, but tesamorelin is a specifically stabilized GHRH analogue that reached formal regulatory approval for one defined medical condition. Sermorelin is a shorter GHRH fragment with a different history, and CJC-1295 is a research compound without that approval. Being related in mechanism does not make them interchangeable, and only tesamorelin has an approved prescription indication.
If tesamorelin is an approved medicine, why does it appear in research-chemical listings?: Approval applies to a specific branded product, dose form, and medical indication delivered under prescription and supervision. Material sold as a research chemical sits entirely outside that framework: it is not the approved product, is not quality-assured for human use, and carries no medical oversight. The existence of an approved version does not make unregulated supply equivalent or safe.
Is a GHRH analogue the same as taking growth hormone directly?: No. Tesamorelin works upstream, stimulating the body's own pituitary to release growth hormone through the GHRH pathway, rather than supplying growth hormone itself. This is a genuine mechanistic distinction often blurred in casual discussion, but both approaches affect the same hormonal axis and carry real physiological consequences, which is why medical supervision matters.
Where can I buy Tesamorelin and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

GH axisApproved vs research use

Compare Tesamorelin

Tesamorelin vs Sermorelin

Sources

EGRIFTA SV (tesamorelin) Prescribing Information — U.S. FDA · accessdata

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10